Is Genelux Common Stock a Good Investment?
Genelux Common Investment Advice | GNLX |
- Examine Genelux Common's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Genelux Common's leadership team and their track record. Good management can help Genelux Common navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Genelux Common's business and its evolving consumer preferences.
- Compare Genelux Common's performance and market position to its competitors. Analyze how Genelux Common is positioned in terms of product offerings, innovation, and market share.
- Check if Genelux Common pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Genelux Common's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Genelux Common stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Genelux Common is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Good | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Genelux Common Stock
Researching Genelux Common's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 17.0% of the company shares are held by company insiders. The book value of Genelux Common was currently reported as 0.97. The company recorded a loss per share of 0.92. Genelux Common had not issued any dividends in recent years.
To determine if Genelux Common is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Genelux Common's research are outlined below:
| Genelux Common is way too risky over 90 days horizon | |
| Genelux Common appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 170 K. Net Loss for the year was (28.3 M) with profit before overhead, payroll, taxes, and interest of 8 K. | |
| Genelux Common generates negative cash flow from operations | |
| Genelux Common has a poor financial position based on the latest SEC disclosures | |
| About 17.0% of the company shares are held by company insiders |
Genelux Common Quarterly Accounts Payable |
|
Genelux Common uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Genelux Common. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Genelux Common's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Genelux Common's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Genelux Common's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-14 | 2023-09-30 | -0.18 | -0.2 | -0.02 | 11 | ||
2024-05-09 | 2024-03-31 | -0.23 | -0.29 | -0.06 | 26 | ||
2024-03-29 | 2023-12-31 | -0.19 | -0.25 | -0.06 | 31 | ||
2023-08-14 | 2023-06-30 | -0.15 | -0.23 | -0.08 | 53 | ||
2023-05-15 | 2023-03-31 | -0.16 | -0.53 | -0.37 | 231 |
Genelux Common's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 138.17 M.Market Cap |
|
Genelux Common's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.91) | (0.96) | |
| Return On Capital Employed | (1.30) | (1.24) | |
| Return On Assets | (0.91) | (0.96) | |
| Return On Equity | (1.67) | (1.59) |
Determining Genelux Common's profitability involves analyzing its financial statements and using various financial metrics to determine if Genelux Common is a good buy. For example, gross profit margin measures Genelux Common's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Genelux Common's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Genelux Common's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Genelux Common. Check Genelux Common's Beneish M Score to see the likelihood of Genelux Common's management manipulating its earnings.
Evaluate Genelux Common's management efficiency
Genelux Common has return on total asset (ROA) of (0.4868) % which means that it has lost $0.4868 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9685) %, meaning that it created substantial loss on money invested by shareholders. Genelux Common's management efficiency ratios could be used to measure how well Genelux Common manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.96 in 2025. Return On Capital Employed is likely to rise to -1.24 in 2025. At this time, Genelux Common's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 29.2 M in 2025, whereas Net Tangible Assets are likely to drop (31.3 M) in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.72 | 0.75 | |
| Tangible Book Value Per Share | 0.72 | 0.75 | |
| Enterprise Value Over EBITDA | (14.58) | (15.31) | |
| Price Book Value Ratio | 15.82 | 16.61 | |
| Enterprise Value Multiple | (14.58) | (15.31) | |
| Price Fair Value | 15.82 | 16.61 | |
| Enterprise Value | 301.8 M | 160.2 M |
The decision-making processes within Genelux Common are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta (1.46) |
Basic technical analysis of Genelux Stock
As of the 22nd of March, Genelux Common retains the Market Risk Adjusted Performance of 0.4644, downside deviation of 5.4, and Risk Adjusted Performance of 0.127. Genelux Common technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Genelux Common's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Genelux Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on Genelux Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Genelux Common insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Genelux Common's Outstanding Corporate Bonds
Genelux Common issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Genelux Common uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Genelux bonds can be classified according to their maturity, which is the date when Genelux Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Genelux Common's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Genelux Common's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.127 | |||
| Market Risk Adjusted Performance | 0.4644 | |||
| Mean Deviation | 5.23 | |||
| Semi Deviation | 4.93 | |||
| Downside Deviation | 5.4 | |||
| Coefficient Of Variation | 749.91 | |||
| Standard Deviation | 6.91 | |||
| Variance | 47.7 | |||
| Information Ratio | 0.1424 | |||
| Jensen Alpha | 1.06 | |||
| Total Risk Alpha | 1.47 | |||
| Sortino Ratio | 0.1822 | |||
| Treynor Ratio | 0.4544 | |||
| Maximum Drawdown | 36.53 | |||
| Value At Risk | (10.00) | |||
| Potential Upside | 12.6 | |||
| Downside Variance | 29.11 | |||
| Semi Variance | 24.26 | |||
| Expected Short fall | (6.66) | |||
| Skewness | 0.8157 | |||
| Kurtosis | 1.33 |
| Risk Adjusted Performance | 0.127 | |||
| Market Risk Adjusted Performance | 0.4644 | |||
| Mean Deviation | 5.23 | |||
| Semi Deviation | 4.93 | |||
| Downside Deviation | 5.4 | |||
| Coefficient Of Variation | 749.91 | |||
| Standard Deviation | 6.91 | |||
| Variance | 47.7 | |||
| Information Ratio | 0.1424 | |||
| Jensen Alpha | 1.06 | |||
| Total Risk Alpha | 1.47 | |||
| Sortino Ratio | 0.1822 | |||
| Treynor Ratio | 0.4544 | |||
| Maximum Drawdown | 36.53 | |||
| Value At Risk | (10.00) | |||
| Potential Upside | 12.6 | |||
| Downside Variance | 29.11 | |||
| Semi Variance | 24.26 | |||
| Expected Short fall | (6.66) | |||
| Skewness | 0.8157 | |||
| Kurtosis | 1.33 |
Consider Genelux Common's intraday indicators
Genelux Common intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Genelux Common stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Genelux Common Corporate Filings
8K | 3rd of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 31st of December 2024 Other Reports | ViewVerify | |
F4 | 30th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Genelux Stock media impact
Far too much social signal, news, headlines, and media speculation about Genelux Common that are available to investors today. That information is available publicly through Genelux media outlets and privately through word of mouth or via Genelux internal channels. However, regardless of the origin, that massive amount of Genelux data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Genelux Common news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Genelux Common relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Genelux Common's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Genelux Common alpha.
Genelux Common Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Genelux Common can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Genelux Common Corporate Management
| Caroline Jewett | VP Quality | Profile | |
| Ralph BSc | Head Affairs | Profile | |
| Sean JD | General Secretary | Profile | |
| Lourie Zak | Chief Officer | Profile | |
| Joseph Cappello | Chief Officer | Profile |
Additional Tools for Genelux Stock Analysis
When running Genelux Common's price analysis, check to measure Genelux Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genelux Common is operating at the current time. Most of Genelux Common's value examination focuses on studying past and present price action to predict the probability of Genelux Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genelux Common's price. Additionally, you may evaluate how the addition of Genelux Common to your portfolios can decrease your overall portfolio volatility.